For healthcare professionals only
Welcome to the new, updated HER2Know
We have expanded our resource library so you can now explore content on HER2 in tumors beyond breast.
Looking for the original HER2Know breast cancer resources?
FEATURED
The importance of reporting discrete HER2 IHC scores
In this case, the patient presented with primary breast cancer classified as HER2-negative.
by Marilyn Bui, MD, PhD
Assessing HER2 IHC with cytoplasmic staining
In this case, the HER2 IHC on a segmental mastectomy specimen from a primary invasive ductal carcinoma showed an unusual cytoplasmic staining pattern.
by Savitri Krishnamurthy, MD
Assessing HER2 IHC with edge artifacts
In this case, the HER2 IHC of a core needle biopsy specimen from an invasive breast carcinoma showed signs of edge artifact.
by Gary Tozbikian, MD
Interpreting HER2 IHC with an extensive in situ component
In this case, there was an extensive in situ component present along with the invasive carcinoma, and HER2 IHC scores were discordant between the two.
by Hannah Wen, MD, PhD
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
The Breast Pathology Faculty share their thoughts on dealing with complexities associated with HER2 IHC assessment.
Decalcified bone specimen: Processing procedures
In this article, Dr. Wei discusses the use of bone specimens as samples for HER2 IHC in metastatic breast cancer.
by Shi Wei, MD, PhD
Unusual staining pattern: Basolateral staining in micropapillary carcinoma
In this article, Dr. Jaffer details the interpretation of biomarker testing in invasive micropapillary carcinomas.
by Shabnam Jaffer, MD
Impact of pre-analytic variables on HER2 IHC results
In this article, Dr. Khoury reviews several different pre-analytic variables and their impact on HER2 IHC assessment.
by Thaer Khoury, MD
Recommendations for testing of cytology specimens
In this article, Dr. Bui discusses the advantages and disadvantages of using cytology samples for HER2 IHC testing in breast cancer.
by Marylin Bui, MD, PhD